Preclinical target validation using patient-derived cells

Nature Reviews Drug Discovery

Volumn 14, Issue 3, 2015, Pages 149-150

  Edwards, Aled M ^a   Arrowsmith, Cheryl H ^a   Bountra, Chas ^b   Bunnage, Mark E ^c   Feldmann, Marc ^d   Knight, Julian C ^e   Patel, Dhavalkumar D ^f   Prinos, Panagiotis ^a   Taylor, Michael D ^g   Sundström, Michael ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c PFIZER INC   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROTEIN KINASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL CULTURE; INFLAMMATORY DISEASE; MOLECULAR MECHANICS; NOTE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RHEUMATOID ARTHRITIS; TUMOR MICROENVIRONMENT; VALIDATION STUDY; CELL LINE; DRUG SCREENING; PATIENT; PRIMARY CELL CULTURE; PROCEDURES; TRANSLATIONAL RESEARCH;

CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; PATIENTS; PRIMARY CELL CULTURE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84924084683     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4565     Document Type: Note

References (3)

1. Bunnage, M. E. Getting pharmaceutical R&D back on target. Nature Chem. Biol. 7, 335-339 (2011).
2. Marshall, J. C. Why have clinical trials in sepsis failed? Trends Mol. Med. 20, 195-203 (2014).
3. Brennan, F. M. et al. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247 (1989).